Summary by Futu AI
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of new senior unsecured notes. The notes, denominated in euros, are to be offered in three tranches with varying maturities and interest rates, which have yet to be determined. The interest on these notes will be paid annually, beginning in 2025. The notes will rank equally with Johnson & Johnson's other unsecured and unsubordinated debt. The company intends to list the notes on the New York Stock Exchange (NYSE) and expects trading to commence within 30 days post-issue. The proceeds from the sale of the notes are intended...Show More